Edition:
United States

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

3.39USD
18 May 2018
Change (% chg)

$-0.24 (-6.61%)
Prev Close
$3.63
Open
$3.32
Day's High
$3.56
Day's Low
$3.24
Volume
293,979
Avg. Vol
150,131
52-wk High
$3.64
52-wk Low
$0.94

Select another date:

Thu, May 17 2018

BRIEF-Arqule Files Prospectus Related To Seconday Offering Of Up To 10.6 Mln Shares

* ARQULE INC FILES PROSPECTUS RELATED TO OFFERING UP TO 10.6 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source http://bit.ly/2IOmvpZ Further company coverage:

BRIEF-Arqule Reports Q1 Loss Per Share Of $0.07

* Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

BRIEF-ArQule Reports Q4 Loss Per Share $0.09

* ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China

* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA

BRIEF-ArQule Files For Offering Of Up To 17.1 Million Shares

* ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: (http://bit.ly/2ivqMQn) Further company coverage:

BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor

* Arqule announces dosing in a registrational trial of fgfr inhibitor, derazantinib, for treatment of intrahepatic cholangiocarcinoma

Select another date: